MANAGEMENT TEAM

Jamie Blundell
CEO

Jamie Blundell brings to Segra over 25 years of experience in senior leadership roles. He has a broad range of B2B and operational expertise with rapidly growing companies in the cannabis, digital media and manufacturing industries. Jamie has previously led operations and business development at corporations that include Yellow Pages and AutoTrader.ca, and most recently acted as President & COO at Cannabis Growth Opportunity Corporation, where he raised $40M in a full prospectus IPO. Through his extensive dealings with M&A, private equity firms, capital markets and large corporate divestitures, he brings a focused and dynamic approach to driving Segra’s growth.

Susan Pan
Vice President, Finance

Susan brings two decades of international experience to her role at Segra. She started her career with China Petroleum & Chemical Corporation, the largest energy company in China, and later joined Siemens Ltd. in China. Recently, she held the position as Controller for Nano One Materials (TSX-V: NNO), and CFO for Aurora Solar Technologies (TSX-V: ACU), both leading technology companies. Susan is a Certified Professional Accountant and holds an MBA.

Dr. Sma Zobayed
Ph.D., Chief Tissue Culture Officer

Dr. Sma Zobayed is a leading specialist in tissue culturing with extensive international experience. Dr. Zobayed holds two patents relating to tissue culture and has published over 50 scientific papers related to his research in the field. He holds a Ph.D. in Plant Tissue Culture from the Department of Biological Sciences at the University of Hull (UK), and has won awards for his tissue culture work from the scientific community. He is a member in good standing with the International Society of Arboriculture, International Association for Plant Tissue Culture and the International Society for Horticultural Sciences.

Dr. John Brunstein
Chief Scientific Officer

Dr. Brunstein is a leading expert on biotechnology, molecular biology, and clinically related topics including clinical trials, assay validation methods and quality systems in regulated industries, with an extensive publication history. He obtained his Ph.D. in Biochemistry from the University of British, working on the molecular biology of viruses, and went on to teach in the Department of Pathology at UBC as Clinical Assistant Professor, where he was recognized with a Faculty Award for Excellence in Research and Discovery and later became the Chief Scientific Officer at the Centre for Translational and Applied Genomics.

Dr. Oliver Corea
Director of Applied Genomics

Dr. Corea is a plant molecular biologist with an academic background in genetic and genomic analysis of specialized plant metabolic pathways. He earned his PhD in Molecular Plant Sciences at Washington State University and worked on large-scale plant genomics projects as a Postdoctoral Fellow at Simon Fraser University and the University of Victoria. His research interests on phenylpropanoid and terpene biosynthesis later drew him to the cannabis industry, where he designed and established two state-of-the-art analytical testing laboratories for cannabis testing and research as Head of Analytical Science at Zenabis Global Inc. At Segra, he will lead cannabis genomics initiatives and help expand Segra’s role as an international leader in cannabis agricultural biotechnology.

Dave Watson
Strategic Advisor

Since 1970, David Watson has traveled extensively to cannabis-producing countries looking for seeds of unusual varieties, and in 1975 established Sacred Seeds, the world’s first cannabis seed company, in California. In 1986, he began Cultivator’s Choice, Amsterdam’s first cannabis seed company, breeding and introducing many foundation sinsemilla varieties still grown today. In 1992, Mr. Watson established HortaPharm BV, the world’s first established medical cannabis corporation, and in 1993 he co-founded the International Hemp Association. Working under license from the Dutch Ministry of Health, HortaPharm established facilities used to breed medical cultivars and conduct cannabis research and development. Mr. Watson formulated HortaPharm’s research goals and created the team led by Dr. Etienne De Meijer that was the first to use STS as a breeding method to “self” cannabis plants and create single cannabinoid cultivars. In 1998, HortaPharm supplied varieties along with organic cultivation and integrated pest management expertise to GW Pharmaceuticals in the United Kingdom and assisted in selecting the cultivars used to produce Sativex® and other GW varieties. Mr. Watson co-authored Hemp Diseases and Pests (2000) with John McPartland and Robert Clarke, contributed to Franjo Grotenhermen’s “Cannabis and Cannabinoids” and Mahmoud El Sohly’s “Marijuana and Cannabinoids,” as well as many other articles.